Biotech Firm Debut Is Getting Into the Contract Manufacturing Business

  • 📰 wwd
  • ⏱ Reading Time:
  • 13 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 68%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

BiotechXBeautyLabs will be a formulation development and contract manufacturing business for white label products.

Debut is dipping its toes into the contract manufacturing business, with the goal of bringing biotech ingredients to the masses.The new business division harnesses end-to-end services, including novel ingredient discovery, pre-clinical testing, formulation development, quality control production, and access to Debut’s IP portfolio consisting of more than 7,000 proprietary claims.

Britton estimated that the division will generate net revenue of $100 million in the next five years. If approved, Debut can receive a follow-on award of up to $100 million to build a U.S.-based bio-industrial manufacturing facility.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

 /  🏆 24. in FR
 

Merci pour votre commentaire. Votre commentaire sera publié après examen.

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

These are top biotech stocks to own for the second half of 2024: OppenheimerThese are top biotech stocks to own for the second half of 2024: Oppenheimer
La source: Investingcom - 🏆 450. / 53 Lire la suite »